GlassScriptPhysician profile
Ralph A Defronzo
NPI 1851408843
$879,625.05
in general payments reported to CMS, 2019-2025
30 companies · $113K in 2025
The $113K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187K · 2020: $179K · 2021: $81K · 2022: $76K · 2023: $100K · 2024: $143K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150K · Consulting Fee: $131K · Travel and Lodging: $51K · Honoraria: $19K · Food and Beverage: $4,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150,103.00 |
| Consulting Fee | $131,332.50 |
| Travel and Lodging | $50,854.09 |
| Honoraria | $18,920.00 |
| Food and Beverage | $4,557.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $328,520.61 | 2019-2024 | Farxiga |
| Corcept Therapeutics | $167,595.75 | 2021-2025 | Korlym |
| Novo Nordisk INC | $150,000.18 | 2019-2025 | Ozempic, Victoza |
| Hikma Pharmaceuticals USA | $66,846.37 | 2020-2024 | |
| Regeneron Pharmaceuticals, INC. | $34,134.87 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $20,880.00 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $14,375.49 | 2019-2020 | |
| Novo Nordisk As | $14,084.53 | 2020-2025 | |
| Pfizer INC. | $12,800.00 | 2021-2024 | |
| Glaxosmithkline, LLC. | $9,833.38 | 2022-2025 | |
| Boehringer Ingelheim (Phil.) INC. | $9,060.00 | 2021 | |
| Renalytix Ai, INC. | $8,688.02 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Abbvie INC. | $8,250.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $8,035.80 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,567.25 | 2020-2023 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim DO Brasil Quimica E Farmaceutical Ltda. | $5,225.00 | 2021 | |
| Astrazeneca Ab | $3,600.00 | 2021 | |
| Azurity Pharmaceuticals, INC. | $3,120.00 | 2025 | |
| Dr.Reddy'S Laboratories,INC. | $2,503.00 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,490.00 | 2020-2021 | |
| Boehringer Ingelheim Rcv Gmbh & Co Kg | $2,471.08 | 2020 | |
| Amgen INC. | $868.35 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $133.07 | 2024 | Recorlev |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Medtronic Vascular, INC. | $125.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $123.63 | 2019 | |
| Madrigal Pharmaceuticals | $92.22 | 2025 | Rezdiffra |
| Eli Lilly and Company | $76.45 | 2024 | Mounjaro |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Defronzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.